Current status and application of proton therapy for esophageal cancer
• Significant dosimetric sparing of organs is seen with protons for esophageal cancer. • Retrospective studies showed improved clinical benefit and lymphopenia with protons. • One randomized trial demonstrated toxicity burden reduction of protons vs. IMRT. • Future larger randomized trials are neede...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Wang, Xin [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells - Han, Xiaobing ELSEVIER, 2021, journal of the European Society for Therapeutic Radiology and Oncology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:164 ; year:2021 ; pages:27-36 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.radonc.2021.09.004 |
|---|
| Katalog-ID: |
ELV056145020 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV056145020 | ||
| 003 | DE-627 | ||
| 005 | 20230624225948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220105s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.radonc.2021.09.004 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001650.pica |
| 035 | |a (DE-627)ELV056145020 | ||
| 035 | |a (ELSEVIER)S0167-8140(21)06724-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |a 540 |q VZ |
| 100 | 1 | |a Wang, Xin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current status and application of proton therapy for esophageal cancer |
| 264 | 1 | |c 2021 | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Significant dosimetric sparing of organs is seen with protons for esophageal cancer. • Retrospective studies showed improved clinical benefit and lymphopenia with protons. • One randomized trial demonstrated toxicity burden reduction of protons vs. IMRT. • Future larger randomized trials are needed to confirm these findings. | ||
| 650 | 7 | |a Intensity modulated radiation therapy |2 Elsevier | |
| 650 | 7 | |a Lymphopenia |2 Elsevier | |
| 650 | 7 | |a Proton therapy |2 Elsevier | |
| 650 | 7 | |a Dosimetry |2 Elsevier | |
| 650 | 7 | |a Esophageal cancer |2 Elsevier | |
| 650 | 7 | |a Total toxicity burden |2 Elsevier | |
| 700 | 1 | |a Hobbs, Brian |4 oth | |
| 700 | 1 | |a Gandhi, Saumil J. |4 oth | |
| 700 | 1 | |a Muijs, Christina T. |4 oth | |
| 700 | 1 | |a Langendijk, Johannes A. |4 oth | |
| 700 | 1 | |a Lin, Steven H. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Han, Xiaobing ELSEVIER |t Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |d 2021 |d journal of the European Society for Therapeutic Radiology and Oncology |g Amsterdam [u.a.] |w (DE-627)ELV00004122X |
| 773 | 1 | 8 | |g volume:164 |g year:2021 |g pages:27-36 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.radonc.2021.09.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 164 |j 2021 |h 27-36 |g 10 | ||
| author_variant |
x w xw |
|---|---|
| matchkey_str |
wangxinhobbsbriangandhisaumiljmuijschris:2021----:urnsauadplctoopooteayo |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.1016/j.radonc.2021.09.004 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001650.pica (DE-627)ELV056145020 (ELSEVIER)S0167-8140(21)06724-4 DE-627 ger DE-627 rakwb eng 570 540 VZ Wang, Xin verfasserin aut Current status and application of proton therapy for esophageal cancer 2021 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Significant dosimetric sparing of organs is seen with protons for esophageal cancer. • Retrospective studies showed improved clinical benefit and lymphopenia with protons. • One randomized trial demonstrated toxicity burden reduction of protons vs. IMRT. • Future larger randomized trials are needed to confirm these findings. Intensity modulated radiation therapy Elsevier Lymphopenia Elsevier Proton therapy Elsevier Dosimetry Elsevier Esophageal cancer Elsevier Total toxicity burden Elsevier Hobbs, Brian oth Gandhi, Saumil J. oth Muijs, Christina T. oth Langendijk, Johannes A. oth Lin, Steven H. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:164 year:2021 pages:27-36 extent:10 https://doi.org/10.1016/j.radonc.2021.09.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 164 2021 27-36 10 |
| spelling |
10.1016/j.radonc.2021.09.004 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001650.pica (DE-627)ELV056145020 (ELSEVIER)S0167-8140(21)06724-4 DE-627 ger DE-627 rakwb eng 570 540 VZ Wang, Xin verfasserin aut Current status and application of proton therapy for esophageal cancer 2021 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Significant dosimetric sparing of organs is seen with protons for esophageal cancer. • Retrospective studies showed improved clinical benefit and lymphopenia with protons. • One randomized trial demonstrated toxicity burden reduction of protons vs. IMRT. • Future larger randomized trials are needed to confirm these findings. Intensity modulated radiation therapy Elsevier Lymphopenia Elsevier Proton therapy Elsevier Dosimetry Elsevier Esophageal cancer Elsevier Total toxicity burden Elsevier Hobbs, Brian oth Gandhi, Saumil J. oth Muijs, Christina T. oth Langendijk, Johannes A. oth Lin, Steven H. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:164 year:2021 pages:27-36 extent:10 https://doi.org/10.1016/j.radonc.2021.09.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 164 2021 27-36 10 |
| allfields_unstemmed |
10.1016/j.radonc.2021.09.004 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001650.pica (DE-627)ELV056145020 (ELSEVIER)S0167-8140(21)06724-4 DE-627 ger DE-627 rakwb eng 570 540 VZ Wang, Xin verfasserin aut Current status and application of proton therapy for esophageal cancer 2021 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Significant dosimetric sparing of organs is seen with protons for esophageal cancer. • Retrospective studies showed improved clinical benefit and lymphopenia with protons. • One randomized trial demonstrated toxicity burden reduction of protons vs. IMRT. • Future larger randomized trials are needed to confirm these findings. Intensity modulated radiation therapy Elsevier Lymphopenia Elsevier Proton therapy Elsevier Dosimetry Elsevier Esophageal cancer Elsevier Total toxicity burden Elsevier Hobbs, Brian oth Gandhi, Saumil J. oth Muijs, Christina T. oth Langendijk, Johannes A. oth Lin, Steven H. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:164 year:2021 pages:27-36 extent:10 https://doi.org/10.1016/j.radonc.2021.09.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 164 2021 27-36 10 |
| allfieldsGer |
10.1016/j.radonc.2021.09.004 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001650.pica (DE-627)ELV056145020 (ELSEVIER)S0167-8140(21)06724-4 DE-627 ger DE-627 rakwb eng 570 540 VZ Wang, Xin verfasserin aut Current status and application of proton therapy for esophageal cancer 2021 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Significant dosimetric sparing of organs is seen with protons for esophageal cancer. • Retrospective studies showed improved clinical benefit and lymphopenia with protons. • One randomized trial demonstrated toxicity burden reduction of protons vs. IMRT. • Future larger randomized trials are needed to confirm these findings. Intensity modulated radiation therapy Elsevier Lymphopenia Elsevier Proton therapy Elsevier Dosimetry Elsevier Esophageal cancer Elsevier Total toxicity burden Elsevier Hobbs, Brian oth Gandhi, Saumil J. oth Muijs, Christina T. oth Langendijk, Johannes A. oth Lin, Steven H. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:164 year:2021 pages:27-36 extent:10 https://doi.org/10.1016/j.radonc.2021.09.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 164 2021 27-36 10 |
| allfieldsSound |
10.1016/j.radonc.2021.09.004 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001650.pica (DE-627)ELV056145020 (ELSEVIER)S0167-8140(21)06724-4 DE-627 ger DE-627 rakwb eng 570 540 VZ Wang, Xin verfasserin aut Current status and application of proton therapy for esophageal cancer 2021 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Significant dosimetric sparing of organs is seen with protons for esophageal cancer. • Retrospective studies showed improved clinical benefit and lymphopenia with protons. • One randomized trial demonstrated toxicity burden reduction of protons vs. IMRT. • Future larger randomized trials are needed to confirm these findings. Intensity modulated radiation therapy Elsevier Lymphopenia Elsevier Proton therapy Elsevier Dosimetry Elsevier Esophageal cancer Elsevier Total toxicity burden Elsevier Hobbs, Brian oth Gandhi, Saumil J. oth Muijs, Christina T. oth Langendijk, Johannes A. oth Lin, Steven H. oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:164 year:2021 pages:27-36 extent:10 https://doi.org/10.1016/j.radonc.2021.09.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 164 2021 27-36 10 |
| language |
English |
| source |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:164 year:2021 pages:27-36 extent:10 |
| sourceStr |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:164 year:2021 pages:27-36 extent:10 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Intensity modulated radiation therapy Lymphopenia Proton therapy Dosimetry Esophageal cancer Total toxicity burden |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| authorswithroles_txt_mv |
Wang, Xin @@aut@@ Hobbs, Brian @@oth@@ Gandhi, Saumil J. @@oth@@ Muijs, Christina T. @@oth@@ Langendijk, Johannes A. @@oth@@ Lin, Steven H. @@oth@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00004122X |
| dewey-sort |
3570 |
| id |
ELV056145020 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056145020</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624225948.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2021.09.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001650.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056145020</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(21)06724-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wang, Xin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current status and application of proton therapy for esophageal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Significant dosimetric sparing of organs is seen with protons for esophageal cancer. • Retrospective studies showed improved clinical benefit and lymphopenia with protons. • One randomized trial demonstrated toxicity burden reduction of protons vs. IMRT. • Future larger randomized trials are needed to confirm these findings.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intensity modulated radiation therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lymphopenia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Proton therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dosimetry</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Esophageal cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Total toxicity burden</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hobbs, Brian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gandhi, Saumil J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Muijs, Christina T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Langendijk, Johannes A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lin, Steven H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:164</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:27-36</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2021.09.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">164</subfield><subfield code="j">2021</subfield><subfield code="h">27-36</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| author |
Wang, Xin |
| spellingShingle |
Wang, Xin ddc 570 Elsevier Intensity modulated radiation therapy Elsevier Lymphopenia Elsevier Proton therapy Elsevier Dosimetry Elsevier Esophageal cancer Elsevier Total toxicity burden Current status and application of proton therapy for esophageal cancer |
| authorStr |
Wang, Xin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00004122X |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 540 VZ Current status and application of proton therapy for esophageal cancer Intensity modulated radiation therapy Elsevier Lymphopenia Elsevier Proton therapy Elsevier Dosimetry Elsevier Esophageal cancer Elsevier Total toxicity burden Elsevier |
| topic |
ddc 570 Elsevier Intensity modulated radiation therapy Elsevier Lymphopenia Elsevier Proton therapy Elsevier Dosimetry Elsevier Esophageal cancer Elsevier Total toxicity burden |
| topic_unstemmed |
ddc 570 Elsevier Intensity modulated radiation therapy Elsevier Lymphopenia Elsevier Proton therapy Elsevier Dosimetry Elsevier Esophageal cancer Elsevier Total toxicity burden |
| topic_browse |
ddc 570 Elsevier Intensity modulated radiation therapy Elsevier Lymphopenia Elsevier Proton therapy Elsevier Dosimetry Elsevier Esophageal cancer Elsevier Total toxicity burden |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
b h bh s j g sj sjg c t m ct ctm j a l ja jal s h l sh shl |
| hierarchy_parent_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| hierarchy_parent_id |
ELV00004122X |
| dewey-tens |
570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00004122X |
| title |
Current status and application of proton therapy for esophageal cancer |
| ctrlnum |
(DE-627)ELV056145020 (ELSEVIER)S0167-8140(21)06724-4 |
| title_full |
Current status and application of proton therapy for esophageal cancer |
| author_sort |
Wang, Xin |
| journal |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| journalStr |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
27 |
| author_browse |
Wang, Xin |
| container_volume |
164 |
| physical |
10 |
| class |
570 540 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Wang, Xin |
| doi_str_mv |
10.1016/j.radonc.2021.09.004 |
| dewey-full |
570 540 |
| title_sort |
current status and application of proton therapy for esophageal cancer |
| title_auth |
Current status and application of proton therapy for esophageal cancer |
| abstract |
• Significant dosimetric sparing of organs is seen with protons for esophageal cancer. • Retrospective studies showed improved clinical benefit and lymphopenia with protons. • One randomized trial demonstrated toxicity burden reduction of protons vs. IMRT. • Future larger randomized trials are needed to confirm these findings. |
| abstractGer |
• Significant dosimetric sparing of organs is seen with protons for esophageal cancer. • Retrospective studies showed improved clinical benefit and lymphopenia with protons. • One randomized trial demonstrated toxicity burden reduction of protons vs. IMRT. • Future larger randomized trials are needed to confirm these findings. |
| abstract_unstemmed |
• Significant dosimetric sparing of organs is seen with protons for esophageal cancer. • Retrospective studies showed improved clinical benefit and lymphopenia with protons. • One randomized trial demonstrated toxicity burden reduction of protons vs. IMRT. • Future larger randomized trials are needed to confirm these findings. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Current status and application of proton therapy for esophageal cancer |
| url |
https://doi.org/10.1016/j.radonc.2021.09.004 |
| remote_bool |
true |
| author2 |
Hobbs, Brian Gandhi, Saumil J. Muijs, Christina T. Langendijk, Johannes A. Lin, Steven H. |
| author2Str |
Hobbs, Brian Gandhi, Saumil J. Muijs, Christina T. Langendijk, Johannes A. Lin, Steven H. |
| ppnlink |
ELV00004122X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/j.radonc.2021.09.004 |
| up_date |
2024-07-06T19:33:31.343Z |
| _version_ |
1803859432668397568 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056145020</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624225948.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2021.09.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001650.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056145020</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(21)06724-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wang, Xin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current status and application of proton therapy for esophageal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Significant dosimetric sparing of organs is seen with protons for esophageal cancer. • Retrospective studies showed improved clinical benefit and lymphopenia with protons. • One randomized trial demonstrated toxicity burden reduction of protons vs. IMRT. • Future larger randomized trials are needed to confirm these findings.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intensity modulated radiation therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lymphopenia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Proton therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dosimetry</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Esophageal cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Total toxicity burden</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hobbs, Brian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gandhi, Saumil J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Muijs, Christina T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Langendijk, Johannes A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lin, Steven H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:164</subfield><subfield code="g">year:2021</subfield><subfield code="g">pages:27-36</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2021.09.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">164</subfield><subfield code="j">2021</subfield><subfield code="h">27-36</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| score |
7.400014 |